Advancing Microbiome Frontiers: Pediococcus acidilactici Research Service
In the rapidly evolving landscape of Live Biotherapeutic Products (LBPs), the gut microbiome has emerged as a cornerstone of human health and a fertile ground for therapeutic innovation. Among the diverse array of beneficial microorganisms, Pediococcus acidilactici stands out as a robust, lactic acid-producing bacterium with profound immunomodulatory and metabolic potential. As a premier Contract Research Organization (CRO) specializing in preclinical microbiome research, Creative Biolabs is proud to offer a comprehensive suite of services dedicated to Pediococcus acidilactici.
Our mission is to bridge the gap between initial strain isolation and clinical readiness. By leveraging cutting-edge multi-omics, advanced in vitro modeling, and sophisticated in vivo disease models, we empower biopharmaceutical companies to unlock the full therapeutic profile of this versatile microorganism. Whether you are investigating its role in inflammatory bowel disease, metabolic syndrome, or pathogen inhibition, our integrated platform provides the rigorous data necessary to accelerate your pipeline. Partner with us to turn the potential of the microbiome into the reality of transformative medicine.
Overview of Pediococcus acidilactici in Live Biotherapeutics
Pediococcus acidilactici is a Gram-positive, non-spore-forming, coccus-shaped bacterium belonging to the family Lactobacillaceae. Historically utilized in the fermentation of vegetables, meat, and dairy products, it has gained significant attention in the medical community due to its status as a "Generally Recognized as Safe" (GRAS) organism and its remarkable resilience to the harsh conditions of the human gastrointestinal tract. Unlike many other probiotics, P. acidilactici can survive high temperatures and highly acidic environments, making it an ideal candidate for shelf-stable oral therapeutics. Its primary mechanism of action involves the production of lactic acid and various bacteriocins-specifically Pediocins-which inhibit the growth of enteric pathogens such as Listeria monocytogenes and Salmonella. Beyond simple pathogen exclusion, recent research highlights its ability to modulate the host immune system by inducing cytokine production and strengthening the intestinal epithelial barrier.
The therapeutic interest in P. acidilactici stems from its metabolic versatility. It possesses the enzymatic machinery to break down complex carbohydrates and produce short-chain fatty acids (SCFAs) like butyrate and acetate. These metabolites serve as primary energy sources for colonocytes and play a vital role in systemic anti-inflammatory signaling. As we move toward a more "mechanistic" understanding of probiotics, P. acidilactici serves as a primary model for studying host-microbe interactions in the context of chronic disease.
Preclinical Research Services for Pediococcus acidilactici
Navigating the preclinical phase of LBP development requires a multidisciplinary approach that combines microbiology, molecular biology, and pharmacology. Our CRO provides a vertically integrated service model designed to address every stage of the P. acidilactici research lifecycle.
We utilize high-throughput screening and specialized assays to quantify the bioactivity of the strain.
Adhesion Assays: Testing the ability of the strain to adhere to human intestinal cell lines (Caco-2/HT29) to predict colonization.
Pathogen Inhibition: Measuring the efficacy of Pediocin production against a panel of clinical pathogens.
Immune Modulation: Using co-culture models of bacteria and peripheral blood mononuclear cells (PBMCs) to measure the induction of IL-10 (anti-inflammatory) versus TNF-alpha (pro-inflammatory).
The transition to animal models is critical for demonstrating therapeutic proof-of-concept. Our facility maintains a variety of specialized mouse and rat models.
Pharmacokinetics of Colonization: Tracking the survival and transit time of the strain through the GI tract using qPCR and fluorescent tagging.
Dose-Response Optimization: Identifying the Minimum Effective Dose (MED) to inform clinical trial design.
Gut Microbiome Modulation: Utilizing 16S rRNA and Metagenomic sequencing to observe how P. acidilactici alters the endogenous microbial community.
This product contains high-quality, intact genomic DNA isolated from Pediococcus acidilactici Lindner Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
Pediococcus acidilactici DNA Standard product can be used for quantitative research and analysis, assay development, verification, and validation, and laboratory quality control.
Research Applications: Targeting Disease with Pediococcus acidilactici
The therapeutic potential of P. acidilactici extends far beyond general gut health. Current research is actively exploring its application in several high-impact disease areas.
Research indicates that P. acidilactici can significantly attenuate the symptoms of Ulcerative Colitis and Crohn's Disease. In preclinical models using Dextran Sulfate Sodium (DSS) to induce colitis, the administration of this strain has been shown to:
Restore the expression of tight junction proteins (Zonulin, Occludin), thereby reducing "leaky gut."
Decrease the infiltration of neutrophils and macrophages into the colonic mucosa.
Upregulate T-regulatory (Treg) cell populations, which are essential for maintaining immune tolerance.
The "gut-liver axis" is a primary target for P. acidilactici research. Studies suggest that the strain can modulate bile acid metabolism and inhibit the absorption of dietary cholesterol. In high-fat diet mouse models, P. acidilactici supplementation has led to:
Reduced body weight gain and adiposity.
Improved insulin sensitivity and glucose tolerance.
Lowered levels of systemic inflammation (LPS-induced endotoxemia).
As a potent producer of Pediocins, this strain is a front-runner for treating enteric infections. It is being researched for its ability to outcompete Clostridioides difficile and restore microbial diversity following heavy antibiotic use. Its resilience to certain antibiotics also makes it a candidate for co-administration during clinical antibiotic therapy to prevent opportunistic infections.
4. Allergic Diseases and the Skin-Gut Axis
Emerging evidence suggests that P. acidilactici can influence systemic TH1/TH2 balance. This has led to research in Atopic Dermatitis (eczema) and food allergies. By promoting a TH1-dominant environment, the strain may suppress the IgE-mediated responses that drive allergic inflammation.
Our Advantages
Selecting a partner for your microbiome research is a decision that impacts the validity and speed of your drug development program. We offer several distinct advantages:
Deep Domain Expertise
Our team consists of PhD-level microbiologists and immunologists who have spent decades studying lactic acid bacteria.
State-of-the-Art Facilities
We operate Class II biosafety labs and germ-free (axenic) animal facilities, allowing for the most controlled microbiome experiments possible.
Regulatory Alignment
Our data packages are designed with IND (Investigational New Drug) submissions in mind, adhering to the latest guidelines for Live Biotherapeutic Products.
Customization and Agility
We recognize that no two strains are alike. We customize every protocol to the unique growth characteristics and therapeutic goals of your specific P. acidilactici candidate.
Advanced Analytics
From metagenomics to metabolomics, we provide a holistic view of the "black box" of the gut, explaining not just if a treatment worked, but how it worked.
Partnering for a Healthier Future
The therapeutic potential of Pediococcus acidilactici represents a significant opportunity in the field of Live Biotherapeutics. Its robust nature, combined with its diverse metabolic and immunomodulatory capabilities, makes it an ideal candidate for addressing some of the most challenging chronic diseases of our time. However, the path from discovery to the clinic is paved with complex regulatory and scientific hurdles.
Our CRO is dedicated to providing the clarity, precision, and rigorous evidence you need to move forward with confidence. By combining our deep microbiological expertise with advanced preclinical platforms, we ensure that your P. acidilactici research is not just successful, but transformative. We invite you to collaborate with us to explore the frontiers of microbiome science and develop the next generation of life-changing therapies.
What makes Pediococcus acidilactici different from Lactobacillus strains?
While both belong to the lactic acid bacteria group, P. acidilactici is often more tolerant of high temperatures (up to 45°C-50°C) and lower pH levels. Its unique production of Pediocins also gives it a distinct antimicrobial profile compared to many Lactobacillus species.
Can you assist with the scale-up of P. acidilactici for clinical trials?
While our primary focus is preclinical research, we provide process development services that optimize fermentation parameters, which can then be transferred to a CMO (Contract Manufacturing Organization) for large-scale production.
How do you ensure the stability of the strain during animal studies?
We perform regular viability checks (CFU counting) on the inoculum and utilize specialized delivery methods (such as oral gavage or microencapsulation) to ensure the bacteria reach the target site in the gut in an active state.
Is P. acidilactici compatible with concurrent antibiotic therapy?
This depends on the specific antibiotic. As part of our service, we perform antibiotic susceptibility testing (AST) to determine which drugs the strain is resistant or sensitive to, allowing for strategic co-administration designs.
What is the typical timeline for a preclinical efficacy study?
Timelines vary based on the disease model. A standard colitis or pathogen challenge study typically takes 8 to 12 weeks from pilot design to final report, whereas metabolic syndrome studies involving long-term diets may take 16 to 20 weeks.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
